36 citations
,
September 2009 in “Journal of Cellular and Molecular Medicine” This review addresses the role of skin-resident adult stem/progenitor cells in skin homeostasis, disease, and cancer development, and reports no new research results.
26 citations
,
October 2018 in “Clinical & Translational Oncology” This review outlines dermatological toxicities associated with targeted cancer therapies and immunotherapies, emphasizing the need for collaborative management by oncologists and dermatologists but reports no new clinical findings.
44 citations
,
September 2015 in “Annals of Oncology” This study reported that targeted anticancer therapies are associated with an increased risk of alopecia compared to placebo, although the risk was lower compared to chemotherapy.
44 citations
,
November 2022 in “Frontiers in Immunology” This review discusses the role of toll-like receptors in cancer treatment, providing an overview of pre-clinical studies and clinical trials on TLR-targeted therapies and noting the challenges and future prospects.
18 citations
,
May 2013 in “Cutaneous and Ocular Toxicology” This study suggests that cutaneous adverse reactions to bortezomib and lenalidomide are more frequent than reported, impacting patients' quality of life and may require dermatological consultation for proper management.
